|Podcasts|October 4, 2022

Long-Time Clinical Trials Exec Looks Back And Forward

Author(s)Lisa Henderson, Andy Studna, Senior Editor

Paula Brown Stafford, CEO of Novan, came to her role via increasing clinical development role responsibilities with Quintiles, now IQVIA. In this podcast, she reflects on her professional experiences, her achievements and her advice for clinical trials professionals.

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related to this article

October 30th, 2026

ACT Brief: Community Research Access, Trustworthy AI Assistants, and Individualized Gene Editing Guidance

In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants.

October 29th, 2026

ACT Brief: Community Trial Access Technology, RBQM Infrastructure, and Digital Clone Use Cases

In today’s ACT Brief, we examine why anti-kickback guidance and EHR-integrated trial matching must work together in community settings, why real-time trials depend on mature risk-based quality management, and how pharma is applying digital clones to predict outcomes.

October 28th, 2026

ACT Brief: Legacy Trial Workflows, Medical Writing Talent Gaps, and Post-Exposure COVID Prevention

In today’s ACT Brief, we examine how legacy workflows pull community clinics away from patient care, why medical writing capacity depends on training rather than technology, and how an antiviral aims to prevent COVID-19 after exposure

October 27th, 2026

ACT Brief: Community Trial Cost Barriers, Measuring What Matters, and Prostate Cancer Approval

In today’s ACT Brief, we examine how cost barriers and site infrastructure limit participation in community trials, why endpoints should reflect what patients actually experience, and how the FDA expanded a prostate cancer combination to an earlier treatment setting.

October 22nd, 2026

ACT Brief: Applied Clinical Trials at 2026 SCRS Global Site Solutions Summit

In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.

October 19th, 2026

ACT Brief: AI Operating Models, Oncology Evidence Trust, and Thyroid Eye Disease Approval

In today’s ACT Brief, we examine how AI is moving into continuous clinical operating models, how trust is built into oncology real-world evidence, and how the FDA approved a self-administered option for thyroid eye disease.

Long-Time Clinical Trials Exec Looks Back And Forward

Related to this article

Trending on Applied Clinical Trials Online

Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda

What Needs to Happen Beyond the Clinical Trial Modernization Act

Walmart and Care Access Plan Three More Clinical Trial Centers in Michigan, Nevada, and Texas

Real-Time Continuous Trials Through the Lens of Risk-Based Quality Management: Why RBQM Is the Infrastructure RTCT Cannot Exist Without

ACT Brief: Community Research Access, Trustworthy AI Assistants, and Individualized Gene Editing Guidance